Interstitial Lung Disease Registry Study: Prospective and Retrospective Observational Study in Austria

Ludwig Boltzmann Institute for Lung Health400 enrolled

Overview

The goal of this registry is to systematically record epidemiological and clinical data throughout the whole interstitial lung disease course - starting with the diagnosis, therapy, follow up of lung function, symptom control, adverse events, medication, survival and death. There are no additional interventions regarding this registry.

Study Type

OBSERVATIONAL

Enrollment

400

Conditions

Interstitial Lung Disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosis of interstitial lung disease * written informed consent Exclusion Criteria: * to not comprehend and rightfully judge participation

Locations (5)

Klinik Hietzing

Vienna, Austria

RECRUITING

Klinik Penzing

Vienna, Austria

RECRUITING

Ludwig Boltzmann Institut for Lung Health

Vienna, Austria

RECRUITING

Outcomes

Primary Outcomes

Mortality

Mortality caused by interstitial lung disease

Time frame: 10 years

Loss of lung function

FVC and DLCO loss within 24 months

Time frame: 2 years

Secondary Outcomes

Prevalence

Prevalence of the different interstitial lung diseases in Austria

Time frame: 10 years

Response to drugs

Response to immunosuppressive/immunomodulating/antifibrotic drugs

Time frame: 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.